M19-025: This phase I trial will begin to understand how safe and tolerable an intravenous cancer drug (ABBV-467) is for the treatment of multiple myeloma in patients who have not responded or got worse on previous treatmentA First In Human Study of the MCL-1 Inhibitor, ABBV-467

Inclusion

• Documented diagnosis of multiple myeloma (MM).

• Measurable disease defined as at least 1 of the following:

  • Serum monoclonal protein >= 1g/dL.
  • Urine M-protein >= 200mg/24 hours.
  • Serum immunoglobulin free light chain (FLC) >= 10 mg/dL (100 mg/L), provided serum FLC ratio is abnormal.
• Relapsed after or are refractory or intolerant to all established MM therapies that are both known to provide clinical benefit and locally available.
• Received at least 3 prior lines of therapy including 1 or more immunomodulatory agents, 1 or more proteasome inhibitors, and 1 or more anti-CD38 monoclonal antibodies.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Adequate hematologic, renal and hepatic function as described in the protocol.
• Echocardiogram with ejection fraction >= 50% and no other clinically significant findings that would increase the participant's susceptibility to cardiac toxicity.